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IMPAK LAWATAN DAN PERKHIDMATAN FARMASI DI RUMAH 
TERHADAP KEPATUHAN DAN PENGETAHUAN UBAT-UBATAN  
DI KALANGAN PESAKIT-PESAKIT HIPERTENSI DI SEREMBAN 
 
ABSTRAK 
Hipertensi merupakan salah satu masalah kesihatan yang kronik di Malaysia berikutan 
peratusan pengidapnya yang tinggi (42.6% dalam tahun 2006), kurangnya kesedaran 
terhadap penyakit ini dan kesannya terhadap kadar morbiditi dan mortaliti.  Tahap 
keakuran rawatan perubatan yang rendah merupakan antara penyebab utama kegagalan 
kawalan penyakit hipertensi.  Oleh itu penyelidikan ini dijalankan bagi menilai tahap 
keakuran pesakit terhadap rawatan perubatan,  kawalan tekanan darah dan tahap 
pengetahuan melalui  ’Perkhidmatan Perawatan Farmasi di Rumah’.  Penyelidikan ini 
dimulakan pada bulan April hingga November 2007 di Daerah Seremban, Negeri 
Sembilan di mana 121 pesakit hipertensi dari Hospital Tuanku Jaafar Seremban telah 
dipilih.  Borang soal selidik berstruktur telah digunakan dalam penyelidikan ini manakala 
tekanan darah diambil dengan menggunakan alat pengukur automatik yang telah 
dikalibrasi (Microlife BP, Model 2BH0).  Seratus tiga pesakit telah menjalani 
penyelidikan ini sepenuhnya di mana 53 pesakit diletakkan dalam kumpulan intervensi 
manakala 50 lagi dalam kumpulan kawalan.  Min (sisihan piawai) umur dikalangan 
peserta adalah 62.2 (10.1) tahun bagi kumpulan intervensi dan 59.4 (9.4) kumpulan 
kawalan.  Majoriti peserta terdiri daripada wanita (56.3%) dan berbangsa Melayu 
(59.2%).  Hasil kajian kumpulan intervensi, didapati peratus keakuran pesakit terhadap 
rawatan perubatan meningkat sebanyak 7.6% selepas sesi kaunseling pertama.  Selepas 
xix 
sesi lawatan dan pendidikan, peratusannya meningkat sebanyak 30.1%.  Jumlah 
peningkatan peratusan keakuran terhadap rawatan perubatan dari fasa pengambilan 
hingga fasa akhir adalah sebanyak 37.7%.  Ini berbeza daripada kumpulan kawalan di 
mana peningkatan sebanyak 4.0% sahaja.  Bagi tekanan darah pula, hasil penyelidikan 
menunjukkan tiada perbezaan yang signifikan didapati dalam kumpulan kawalan 
manakala kumpulan intervensi pula menunjukkan penurunan tekanan darah yang sangat 
signifikan (p<0.05) di mana min (sisihan piawai) tekanan darah sistolik menurun 
daripada 147.0 mmHg (23.9) kepada 135.9 mmHg (21.8) p<0.05 dan min tekanan darah 
diastolik pula daripada 86.8 mmHg (17.7) kepada 81.5 mmHg (14.2) p<0.05.  
Penyelidikan berkaitan kesedaran dan pengetahuan terhadap penyakit dan rawatan pula, 
kumpulan intervensi menunjukkan peningkatan yang signifikan setelah menjalani sesi 
kaunseling, perundingan dan pendidikan di rumah.  Kesemua 6 soalan tersebut 
menunjukkan peningkatan lebih daripada 30%.  Kesimpulannya, program farmasi seperti 
Perkhidmatan Rawatan Farmasi di Rumah telah terbukti dapat meningkatkan tahap 
keakuran terhadap rawatan perubatan,  pengetahuan pesakit dan seterusnya 
mengurangkan tekanan darah pesakit-pesakit hipertensi di Seremban.   
 
Kata kunci:  hipertensi, tekanan darah, kepatuhan , lawatan rumah pesakit, farmasi, 
pendidikan pesakit, pengetahuan  
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IMPACT OF PHARMACIST HOMECARE SERVICE ON  
MEDICATION ADHERENCE AND KNOWLEDGE  
AMONG HYPERTENSIVE PATIENTS IN SEREMBAN 
 
ABSTRACT 
 
Hypertension is one of the major public health problems in Malaysia due to its 
high prevalence (42.6% in 2006), lack of awareness amongst the general population, its 
poor control and its impact on cardiovascular morbidity and mortality.  A common reason 
for inadequate control of hypertension is low adherence with antihypertensive medicine 
regimen.  Therefore, this research was conducted to assess and evaluate patients’ 
adherence and to examine the impact of “Pharmacist Homecare Service (PHS)” provision 
on the patients’ adherence, blood pressure reduction and knowledge among hypertensive 
patients.  The research was conducted from April to November 2007 in Seremban, Negeri 
Sembilan.  A total of 121 patients from Hospital Tuanku Jaafar Seremban were 
interviewed using a validated structured questionnaire and blood pressure was measured 
with a calibrated automated device (Microlife BP, model 2BH0).  Upon consent, 60 
patients were recruited into the normal counselling group (control group) and the other 61 
patients were recruited into the PHS group (intervention group).  At the end of study 
period, only 103 participants completed the 6 months study, 53 in the intervention group 
and the rest in the control group.  The mean (SD) age of the study population was 62.2 
(10.1) years for the intervention group and 59.4 (9.4) years in the control group.  Most of 
the patients were female (56.3%) and Malay ethnics constituted the majority of patients 
xxi 
(59.2%).  In the intervention group, percentage of adherence increased by 7.6% after 
normal counselling during recruitment; and increased by 30.1% after education session 
during home visit.  The increment of adherence from recruitment to final assessment 
(home visit 2) was 37.7%.  Whereas in the control group, percentage of adherence only 
increased by 4.0% after normal counselling during recruitment.  There were no 
significant different in mean blood pressure of control group (p>0.05) whereas in the 
intervention group there was significant reductions (p<0.05) in the systolic blood 
pressure mean (SD) from 147.0 mmHg (23.9) to 135.9 mmHg (21.8) p<0.05 and diastolic 
blood pressure mean from 86.8 mmHg (17.7) to 81.5 mmHg (14.2) p<0.05.  For 
awareness and knowledge of disease and therapy, the intervention group showed 
significant difference between the knowledge assessments with regard to the consultation, 
counselling and patients’ education in the intervention group.  The percentage of 
knowledge for all questions was increased by more than 30%.  Therefore, a pharmacy 
care program such as “Pharmacist Homecare Service” leads to increases in medication 
adherence, medication persistence, knowledge and clinically reductions in blood pressure 
among hypertensive patients in Seremban.  
 
Keywords:  hypertension, blood pressure, adherence, home visit, pharmacist, patient 
education, knowledge 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1.0  Pharmaceutical Care  
1.1.1   Introduction  
The role of pharmacist in the healthcare system had changed over the last two 
decades.  Pharmaceutical care is a way of dealing with patients and their medication.  It is 
a concept that deals with the way people should receive and use medication, and 
instructions for the use of medicines.  It also deals with responsibilities, medication 
surveillance, counselling, outcomes of care, information about disease states and lifestyle 
issues.   
Pharmaceutical care concept was first described by Mikeal et al. as ‘the care that a 
patient requires and receives which assures safe and rational use of drugs’ (Mikael et al., 
1975).   Brodie and colleague were the first to give a more complete definition of 
pharmaceutical care.  They stated ‘pharmaceutical care includes the determination of the 
drug needs for a given individual and the provision not only the drugs required but also of 
the necessary services (before, during or after treatment) to assure optimally safe and 
effective therapy (Brodie et al., 1980).  It includes a feedback mechanism as a means of 
facilitating continuity of care by those who provide it.    
In 1987, Hepler formulated his first definition of pharmaceutical care which the 
commitment to the patient became apparent: ‘a covenantal relationship between a patient 
and a pharmacist in which the pharmacist performs drug-use-control functions (with 
appropriate knowledge and skill) governed by awareness of and commitment to the 
3 
patients’ interest’ (Hepler, 1987).  It is designed to improve the quality of care of patients 
and improve their quality of life. 
Strand, in 1992, published a new definition with Cipolle and Morley, in which the 
patients’ central position in the process receives even more emphasis.  ‘Pharmaceutical 
Care is that component of pharmacy practice which entails the direct interaction of the 
pharmacist with the patient for the purpose of caring for patients drug-related needs’ 
(Strand et al., 1992).  In 1997, she redefined pharmaceutical care as: ‘A practice for 
which the practitioner takes responsibility for a patient’s drug therapy needs and is held 
accountable for this commitment’ (Van Mil, 2000).   
The goal of pharmaceutical care is to improve and individual patients’ quality of 
life through achievement of definite medication-related therapeutic outcome.  This 
involves three major functions (American Society of Hospital Pharmacists, 1993):  
a. identifying potential and actual medication-related problems 
b. resolving actual medication-related problems 
c. preventing potential medication-related problem 
 
In pharmaceutical care, the direct relationship between an individual pharmacist 
and an individual patient is that of a professional covenant in which the patient’s safety 
and well-being are entrusted to the pharmacist, who commits to honouring that trust 
through competent professional actions that are in the patient’s best interest.  Although 
pharmaceutical care has been accepted among pharmacy professionals but there are some 
barriers to the provision of pharmaceutical care (Van Mil, 2000).  These barriers are 
outlined in Table 1.1. 
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Table 1.1: Barriers to the provision of pharmaceutical care (Van Mil, 2000) 
 
A Resources 
1 Lack of money (reimbursement)  
2 Lack of time  
3 Lack of space in pharmacies  
4 Lack of software for medication assessment  
5 No clinical patient data available  
6 Lack of trained staff  
7 Lack of protocols or consensus reports for treatment  
B Attitude and opinions 
1 Attitude/opinion of staff  
2 Attitude/opinion of other professionals  
3 Attitude/opinion of practicing pharmacists (product orientation) 
 
4 Attitude of pharmacy owner (the boss)  
5 Lack of vision on professional development  
C Education 
1 Lack of clinical education  
2 Lack of education in communication skills  
3 Lack of education in social pharmacy  
4 Lack of education on health systems/public health  
D Skills 
1 Lack of skills for medication assessment  
2 Lack of communication skills of pharmacist  
3 Lack of documentation skills of pharmacists  
4 Lack of management skills  
E Environment 
1 Legal barriers  
2 National health care structure in general  
3 Inertia of pharmacists as a group  
4 Privacy problems  
 
 
Pharmaceutical care is applicable and achievable by pharmacists in all practice 
settings.  It is not a matter of formal credentials or place of work (American Society of 
Hospital Pharmacists, 1993).  It is a matter of a direct personal, professional, responsible 
relationship with a patient to ensure that the patient’s use of medication is optimal and 
leads to improvements in the patient’s quality of life.  Pharmacists should commit 
themselves to continuous care on behalf of individual patients.  They bear responsibility 
for ensuring that the patient’s care is ongoing despite work-shift changes, weekends and 
holidays. 
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1.1.2    Homecare Service (Community Outreach / Home Visit) 
Homecare service refers to health services, health education and health promotion 
strategies directed to the entire population, specifically to high risk and underserved 
groups and individuals (Hill et al., 2000).  It is an activity at the interface of medicine and 
public health, an area that is the focus of community nursing.  Its goal is to reach those 
who have not been reached by usual methods for the purpose of gaining knowledge, 
information, and access to and utilization of health services.  Homecare service is an 
essential component of comprehensive programs to promote health, as well as prevent 
and/or control disease and related risk factors (Hill et al., 2000).  The key principles are 
active community participation and partnership, planning program implementation and 
evaluation.  Effective interventions combine persuasive communications, interpersonal 
relationships, skills training and community organizing (Hill et al., 2000).  It has proved 
hypertension control by linking health profession-healthcare organizations, and current or 
potential patients with resources in patients’ communities. 
Clinical hypertension care and control programs, which include community 
outreach, provide three important lessons (Alvarez et al., 2001): 
a. Clinicians can use resources in the community to directly enhance their care of 
patients, thus improving long-term control of hypertension and reducing 
associated target organ damage 
b. Community programs provide reinforcement of the clinician’s recommendation 
and teaching efforts 
c. Physicians, nurses and other health care providers can provide homecare services 
which include screening, case finding, referral, education, and monitoring and 
6 
leadership by accepting referrals, promoting outreach programs, and acting as 
consultants 
 
1.1.3   Role of Pharmacists in Home Care Services: A Literature Review 
 Lowe and colleagues in the year 2000 had conducted a medication review study 
for older people in a suburban area of Leeds (Lowe et al., 2000a).  Patients fulfilling the 
inclusion criteria were recruited and randomly allocated to the intervention or control 
group and received three visits from a clinical pharmacist.  One hundred and fifty two 
patients completed the study; 73 patients in the intervention group who received 
medication review and educational; and 79 patients in the control group received standard 
medical care.  The adherence score for patients in the intervention group was 91.3% 
(95% CI: 88.7 to 93.9) and control group 79.5% (95% CI: 74.7 - 84.3); p<0.0001.  The 
overall change in knowledge for both groups between the first and third visit was highly 
significantly different between the two (p<0.0001).  
The study shows that medication review and patient education by pharmacist in 
the community can significantly improve patient’s knowledge of and adherence with 
medication in short term.  By combining a medication review with in-depth medicine 
education, the program offers a way of maximizing the benefits that patients can receive 
from their medicines.  Pharmacist was also able to negotiate the medication regimen with 
the patient and doctor. 
 A cross-sectional study was done by Sorensen and colleagues in 2005 to 
determine the association between medication-related risk factors and poor patient health 
outcomes from observations in the patients’ homes (Sorensen et al., 2005).  Two hundred 
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and four patients were visited in this study.  Overall, recent worsening of health status 
was seen in 55 (27.0%) patients and 51 (25.0%) patients experienced an adverse drug 
event over the preceding 3 months.  Of the medication-related risk factors examined, 
patients were most frequently confused by generic and trade names (114 patients or 
55.9%) while poor adherence was reported by 107 (52.5%) patients.  Some 68 (33%) 
patients risked therapeutic duplications and some patients had more than one duplicated 
set of items.  The most frequently duplicated items were cardiovascular medications.  In 
conclusion, the major findings of this study include the identification of considerable 
relationships between the medication-related risk factors and health outcomes which 
support the theory that polypharmacy and medication-related risk factors as a result of 
polypharmacy are correlated with poor health outcomes. 
 Another study also was done by Sorensen and colleagues in 2006 to determine the 
prevalence and inter-relationships of medication-related risk factors for poor patient 
health outcomes identifiable through ‘in-home’ observation (Sorensen  et al., 2006).  
Home visits were conducted at 204 patients’ house by pharmacists (87.3%) or general 
practitioners (12.7%) as part of the intervention in a randomized controlled trial.  Of the 
medication related risk factors examined, patients were most frequently confused by 
generic and trade names (55.9% of patients) while poor adherence was reported with the 
second highest frequency (52.5%).  These medication related risk factors could be 
improved by counselling and education programme.  In conclusion, visiting patients’ 
homes may identify medication related risk factors and inter-relationships that may no be 
evident by other methods. 
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1.2.0  Epidemiology of Hypertension   
 
Hypertension, most commonly referred to as “high blood pressure”, is a medical 
condition in which the blood pressure is chronically elevated.  Hypertension is usually 
first considered during periodic check-up visits or as part of ordinary screening when 
patients are seen for unrelated minor illness.  The initial evaluation should consist of a 
careful medical history, appropriately comprehensive physical examination and necessary 
tests.   
The most recent definition of hypertension as released by the Seventh Report of 
the Joint National Committee on Prevention, Detection, Evaluation and Treatment of 
High Blood Pressure (JNC 7) (Chobanian et al., 2003) is a systolic blood pressure 
≥140mmHg or diastolic blood pressure ≥ 90mmHg.  Systolic pressure is the highest 
arterial pressure during the contraction of the left ventricle of the heart and diastolic 
pressure is the lowest arterial pressure during relaxation and dilatation of the ventricles of 
heart when it refills with blood.  Perhaps the most important change is the new 
classification of “pre-hypertension” (SBP 120 -139mmHg or DBP 80 - 89mmHg).  Table 
1.2 shows the classification of blood pressure according to JNC7.   Pre-hypertension is 
not a disease category, it is a designation chosen to identify individuals at high risk of 
developing hypertension, so that both patients and clinicians are alerted to the risk and 
encouraged to intervene and prevent the delay of disease from developing.  After 
evaluating hypertensive patients, decisions will be made regarding goals for treatment 
and strategies for achieving these goals.   
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Table 1.2:  Blood Pressure Classification According to JNC 7 (Chobanian et al., 2003) 
 
BP Classification SBP mmHg DBP mmHg  
Normal <120 and <80  
Pre-hypertension 120-139 or 80-89  
Stage 1 Hypertension 140-159 or 90-99  
Stage 2 Hypertension ≥160 or ≥ 100  
 
 
In general, some combination of lifestyle change and drug therapy will be 
recommended.  When the pressure is higher, drug treatment will be started immediately.   
For those with pressures in the range of 140 to 150mmHg systolic and 90 to 100mmHg 
diastolic, without target organ damage, initial non-pharmacologic choices, particularly 
weight reduction, with or without reduced salt intake may be appropriate.   
 
1.2.1  Causes of hypertension 
The exact causes of hypertension are not known.  Several factors and conditions 
may play a role in its development, including overweight (obesity), lack of physical 
activity, too much salt in the diet, smoking, excessive alcohol consumption, stress, old 
age, genetics, family history of high blood pressure, chronic kidney disease and adrenal 
and thyroid disorders. 
A study by Anderson and Slocum-Dickson Medical Group shows that increased 
age is associated with a significant increase in the prevalence of hypertension and 
especially of systolic hypertension after age 60 years.  Increased obesity between ages 
30-50 years is associated with significant increases in diastolic blood pressure (Anderson 
Jr. G.H. and Slocum-Dickson Medical Group, 1999). 
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Weight reduction and sodium reduction are recommended for all prehypertensive 
and hypertensive patients. In Trial of non-pharmacologic Interventions in the Elderly 
(TONE), reducing sodium to 80mmol (2g) per day reduced blood pressure over 30 
months, and about 40% of those on the low-salt diet were able to discontinue their 
antihypertensive medications (Appel LJ et al., 2001).   Weight loss of as little as 4.5kg 
reduces blood pressure and prevents hypertension in a large proportion of overweight 
persons, although the ideal is to maintain normal body weight (The Trials of 
Hypertension Prevention Collaborative Research Group, 1997). 
Chronic hypertension is becoming increasingly common in adolescence and is 
generally associated with obesity, sedentary lifestyle, smoking and a positive family 
history of hypertension.  Lifestyle interventions should be recommended for all children 
with hypertension, with pharmacological therapy instituted for higher levels of blood 
pressure or if insufficient response to lifestyle modifications occurs (Chobanian et al., 
2003). 
 
1.2.2 Sign and Symptoms  
There are usually no symptoms or signs of hypertension.  In fact, nearly one-third 
of those who have it, do not know it.  The only way to know if you have hypertension 
definitely is, to have your blood pressure checked.  Some people with severe high or a 
rapid rise in blood pressure may experience headaches, dizziness, fatigue, blurred vision, 
facial flushing and tinnitus (Bahagian Pendidikan Kesihatan, 2005).   
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1.2.3 Complication  
While elevated blood pressure alone is not an illness, it often requires treatment 
due to its short and long term effects on many organs (Chobanian et al., 2003).  
Hypertension is usually accompanied by other cardiovascular risk factors and is 
metabolically linked to dyslipidemia, glucose intolerance, abdominal obesity and 
hyperinsulinemia.  About half of the persons with hypertension have two or more other 
accompanying risk factors.  The risk is increased for (Stamler et al., 1993): 
a. Cerebrovascular accident (CVA or strokes) 
b. Myocardial infarction (heart attack) 
c. Hypertensive cardiomyopathy (heart failure) 
d. Hypertensive retinopathy (damage to the retina) 
e. Hypertensive nephropathy (chronic renal failure) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1:  Hypertension: A significant cardiovascular and renal disease risk factor 
                   (CHD: coronary heart disease, CHF: chronic heart failure and LVH: left  
                    ventricular hypertrophy) 
Hypertension 
Stroke 
Renal 
disease 
CHD CHF 
LVH 
↑ Morbidity 
↑ Disability Peripheral 
vascular disease 
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  Hypertension represents a potent risk factor for cardiovascular, peripheral 
vascular and renal disease (Stamler et al., 1993, McMahon et al., 1990)  The higher the 
blood pressure, the greater is the likelihood of myocardial infarction, heart failure, stroke, 
and kidney disease.  According to the American Heart Association, cardiovascular 
disease is the number one killer in the United States.  It been estimated that more than 
2,600 people die of heart disease every day, which translates into one cardiovascular 
death every 33 seconds (Saunders, 2007).  Each year, heart disease (30.4%) kills more 
Americans than cancer (23%) (Centers for Disease Control and Prevention, 2000)  Until 
the year 2005, it was the number one cause of death and disability in the United States 
and most European countries. 
 
1.2.4   White-coat Hypertension  
A higher BP in the physician’s presence compared with out-of-office BP was 
reported more than 60 years ago.  Today, clinicians are far more familiar with this 
phenomena but uncertainty remains about the optimal management of these patients.  The 
clinical importance of white-coat hypertension has been recognized and most consensus 
groups, recommend ambulatory monitoring for the patient with that diagnosis (Pickering, 
1996).  White coat hypertension is a phenomenon in which patients exhibit elevated 
blood pressure in a clinical setting but not when recorded by themselves at home.  It is 
believed that this is due to the anxiety some people experienced during clinic visits. 
There are many potential advantages when white-coat hypertension was detected: 
1. patients with white-coat hypertension may not require drug therapy and 
substantial cost savings may accrue, 
13 
2. a better diagnostic and prognostic risk assessment for individual patients may be 
possible and 
3. clinical drug studies can exclude white-coat hypertensive who may not respond to 
drug therapy in the same manner as sustained hypertensive patients (Mansoor and 
White, 1994). 
 
1.2.5   Hypertension Treatment 
 
 Non-pharmacological management plays an important role in the management of 
hypertension (Silaste et al., 2000).  Hypertension is typically treated by making changes 
in lifestyle and with medication therapy.  Lifestyle changes include losing weight, 
stopping smoking, eating a healthy diet such as the Dietary Approaches to Stop 
Hypertension (DASH) diet, which includes reducing sodium and getting sufficient 
exercise (Ministry of Health et al., 2008).  
 
 
1.2.5.1   Lifestyle Modification  
There is universal agreement about the role of lifestyle modification in the 
management of hypertension, including those with high-normal blood pressure, 
particularly where there is a strong family history.  Lifestyle modifications can be 
difficult to apply in the population at large and in the long-term.  The ability of non-
pharmacologic interventions to reduce mortality and morbidity in hypertension has not 
been shown directly (Table 1.3).  Application of lifestyle intervention should not delay 
the introduction of drug therapy, especially in high-risk patients.   
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Lifestyle measures that helps to reduce blood pressure include (Williams et al., 
2004a): 
a. Weight reduction 
b. Reduced salt, total fat and saturated fat intake 
c. Limitation of alcohol consumption and cessation of smoking 
d. Increased physical activity 
e. Increased fruit and vegetable consumption 
 
Weight loss of as little as 4.5kg reduces blood pressure and/or prevents 
hypertension in a large proportion of overweight persons (The Trials of Hypertension 
Prevention Collaborative Research Group, 1997).  Blood pressure is also benefited by 
adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan which is a 
diet rich in fruits, vegetables and low fat dairy products with a reduced content of 
cholesterol (U.S. Department of Health and Human Services, 2006).  Combination of two 
or more lifestyle modifications can achieve even better results (Chobanian et al., 2003). 
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Table 1.3: Lifestyle Modifications To Prevent and Manage Hypertension*  
                        (Chobanian et al., 2003) 
 
Modification Recommendation Approximate SBP Reduction (Range)** 
Weight reduction Maintain normal body weight (body mass index  18.5-24.9kg/m²) 5-20 mmHg / 10kg 
Adopt DASH eating 
plan 
Consume a diet rich in fruits, 
vegetables, and low-fat dairy products 
with a reduced content of saturated and 
total fat 
8-14 mmHg 
Dietary sodium 
reduction 
Reduce dietary sodium intake to no 
more than 100 mmol per day (2.4 g 
sodium or 6 g of sodium chloride 
2-8 mmHg 
Physical activity 
Engage in regular aerobic physical 
activity such as brisk walking (at least 
30 minutes per day, most days of the 
week) 
4-9 mmHg 
Moderation of alcohol 
consumption 
Limit consumption to no more than 2 
drinks per day in most men and to no 
more than 1 drink per day in women 
and lighter-weight persons 
2-4 mmHg 
 
Note:  *  For overall cardiovascular risk reduction, stop smoking 
**The effects of implementing these modifications are dose and time   
   dependent and could be greater for some individuals 
  
 
1.2.5.2   Medication Therapy 
 
The ultimate public health goal of antihypertensive therapy is to reduce 
cardiovascular and renal morbidity and mortality.  The aim of treatment should be blood 
pressure control to <140/90mmHg for most patients, and lower in certain context such as 
diabetes or kidney disease (<130/80mmHg).  Therapy begins with lifestyle modification, 
and if the blood pressure goal is not achieved, thiazide-type diuretics should be used as 
initial therapy for most patients, either alone or in combination with one of the other 
classes (Table 1.4).  There are many classes of medications for treating hypertension, 
called antihypertensive which act by lowering blood pressure.  The JNC-7 guidelines 
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recommend initiating two antihypertensive agents for patients whose systolic BP is 
20mmHg above their goal.  Commonly used medications for the treatment of 
hypertension in Malaysia include (Ministry of Health et al., 2002, Ministry of Health et 
al., 2008): 
a. Diuretics  
The use of diuretics is well established in the treatment of hypertension, cheap 
and the most widely used antihypertensive agents (Ministry of Health et al., 
2008).  They help the kidneys eliminate sodium and water from the body 
(decreases blood volume).  Diuretics may be used as initial therapy. They also 
enhance the efficacy of other classes of antihypertensive drugs when used in 
combination (Sulaiman et al., 2001).  Thiazide diuretics are one of the most 
widely used antihypertensive agents.  In the elderly with no co-morbid 
conditions, diuretics are the drugs of choice in the treatment of systolic-
diastolic hypertension and isolated systolic hypertension.  Diuretics not only 
reduce the incidence of fatal and non-fatal strokes but also cardiovascular 
morbidity and mortality (Brown et al., 2000). In The Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study, 
which involved more than 40 000 hypertensive individuals,109 there were no 
differences in the primary CHD outcome or mortality between the thiazide-
type diuretic chlorthalidone, the lisinopril or the amlodipine (The ALLHAT 
Officers and Coordinators for the ALLHAT Collaborative Research Group, 
2002). Examples of diuretics include frusemide, chlorothiazide, 
hydrochlorothiazide and indapamide.  Common side effects are frequent 
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urination, muscle cramps, tiredness, dizziness, headache, dehydration, nausea, 
vomiting and sore throat. 
 
b. Alpha Blockers 
The peripheral alpha 1-adrenergic blockers lower blood pressure by reducing 
peripheral resistance, prostatic and urethral smooth muscle tone and provide 
symptomatic relief for patients with early benign prostatic hypertrophy (BPH) 
(Gillenwater et al., 1995).  Examples of alpha blockers include doxazosin, 
prazosin and terazosin.  Postural hypotension is a commonly known side 
effect especially at the initiation of therapy. 
 
c. Beta Blockers (BB) 
Beta blockers have long been established in the treatment of hypertension 
with angina, tachyarrhythmias or previous myocardial infarction where they 
have been shown to reduce cardiovascular morbidity and mortality (Ministry 
of Health et al., 2008).  Certain beta blockers such as carvedilol and bisoprolol 
have been shown to be beneficial in patients with heart failure.  Beta blockers 
are contraindicated in patients with obstructive airways disease, severe 
peripheral vascular disease and heart block.  Examples of beta blockers 
include atenolol, bisoprolol, carvedilol, labetalol, metoprolol and propanolol.  
Common side effects are drowsiness, weakness, dizziness, dry mouth, eyes 
and skin, cold hands and feet, slow heartbeat, nightmares and erectile 
dysfunction. 
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d. Angiotensin Converting Enzyme Inhibitors (ACEIs)   
ACEIs are effective in lowering blood pressure, well tolerated and do not have 
adverse effects on lipid and glucose metabolism.  ACEIs have been shown to 
reduce mortality and morbidity in patients with congestive heart failure (The 
SOLVD Investigators, 1992), post myocardial infarction and cardiovascular 
risk patients with reduced left ventricular ejection fraction (The AIRE 
Investigator, 1993).  In diabetic patient, ACEIs have been shown to reduce 
cardiovascular mortality, proteinuria and retard the progression of renal 
disease.  Examples of ACEIs include captopril, enalapril, fosinoprol, lisinopril, 
perindopril, quinapril and ramipril.  The common side effect is persistent dry 
cough. 
 
e. Calcium Channel Blockers (CCBs) 
Long-acting CCBs have been shown to be safe and effective in lowering 
blood pressure, both as first-line agents and in combination with other classes 
of antihypertensive drugs (Dahlof et al., 2005, Julius et al., 2004). It may also 
be useful in treating hypertensives with coronary heart disease (Davis et al., 
2002).  Examples of CCBs include amlodipine, diltiazem, felodipine, 
nifedipine and verapamil.  Common side effects are headache, nausea, 
vomiting, ankle oedema and flushes on the face. 
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f. Angiotensin Receptor Blockers (ARB) / Angiotensin  II Antagonists 
ARBs are specific angiotensin II receptor antagonists with many properties 
similar to those of ACEIs.  Unlike ACEIs, persistent dry cough is less of a 
problem.  ARBs are beneficial in the treatment of early and advanced type 2 
diabetic nephropathy (Brenner et al., 2001) and may reduce the incidence of 
major cardiac events in patients with heart failure (McMurray et al., 2003) 
hypertensive LVH and diastolic heart failure (Yusuf et al., 2003).  Examples 
of ARBs include candesartan, irbesartan, losartan, telmisartan and valsartan. 
 
g. Combination Products (usually contain hydrochlorothiazide (HCTZ) and 
one other drug) 
 
Although effective blood pressure control can be achieved in most patients who 
are hypertensive, more than two-thirds of hypertensive individuals cannot be controlled 
on one drug and will require two or more antihypertensive agents selected from different 
dug classes.  In ALLHAT, 60% of those blood pressure was controlled to <140/90 
mmHg received two or more agents and only 30% overall were controlled on one drug 
(Cushman WC et al., 2002).  Using two complementary antihypertensive agents in 
combination will always result in greater efficacy and fewer side effects than high-dose 
monotherapy (Neutel JM, 2006). 
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1.2.5.3   Current Antihypertensive Prescribing Practices 
 In the United States, a study compared National Health and Nutrition 
Examination Survey (NHANES) III 1988 –1994 (n=4933) and NHANES 1999–2002 
(n=3249) data was done by Gu and colleagues to understand current medication 
utilization patterns among hypertensive, this study to examine trends and patterns of 
antihypertensive medication use among US adults with hypertension (Gu et al., 2006).  
Between 1988–1994 and 1999–2002, ACE inhibitor monotherapy use significantly 
increased from 6.2% to 8.5%, whereas monotherapy use of a diuretic or BB decreased 
from 4.9% and 7.1% to 2.7% and 5.1%, respectively.  When monotherapy and 
polytherapy were considered together, diuretics remained the most commonly used 
antihypertensive drug class during 1988–1994 (27.8%) and 1999–2002 (28.7%).  Use 
remained stable across both time periods for most drug classes, except for ACE inhibitors, 
for which was significant increase in use (15.2% versus 23.8%). Overall, 
antihypertensive polytherapy use among hypertensive increased significantly between 
1988–1994 and 1999–2002 from 29.1% to 35.8% (Figure 1).  The used of polytherapies 
containing a CCB, BB, or ACEI substantially increased by 30%, 42%, and 68%, 
respectively. 
 In the United Kingdom, one survey of 21024 patients from England and Wales 
was done by Walley and colleagues to describe the management of newly diagnosed 
hypertension between January 1993 and December 1997, and were followed for 4 years 
(Walley et al., 2003).  This survey showed that diuretics was the most widely prescribed 
first line treatments (32.0%) followed by beta blockers (22.2%).  The continuation rates 
for first-line therapy declined most sharply over the first year (at which point average 
continuation rates reached 69%).  Whilst these patterns were similar for the different classes 
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of drug, continuation rates for ACE inhibitors/ARB were significantly greater than for other 
classes at 18 and 48 months (P50.01, chi-squared=64.80 at 12 months and 130.04 at 48 
months). 
 A study published in 2008 by Wong and colleagues analyzed 67,028 patients 
prescribed anti-hypertensive agents from government primary care clinics of Hong Kong 
from January 2004 to June 2007 (Wong et al., 2008).  The study evaluated the prescribing 
patterns, discontinuation and switching profiles of antihypertensive agents and their 
associated factors in one Hong Kong Chinese population.  The most commonly 
prescribed drugs were CCBs (49%), BBs (46%) and ACEIs (19%).  Thiazide diuretic 
prescribing was low (13%) and on the decline (14% in 2004 to 12% in 2007). Prescribing 
of ACEIs was rising (16% in 2004 to 23% in 2007).  Drug discontinuation was highest 
for BBs (21%) and lowest for CCBs (12%). The high rates of discontinuation in BBs 
remained apparent after controlling for confounding variables. Switching was less 
common than discontinuation and was most likely with thiazide diuretics.  
In Malaysia, the National Medicines Use Survey (NMUS) conducted several 
surveys in order to capture data at the various levels of medicines supply and distribution 
system in the country.  The surveys covered Ministry of Health Malaysia, private 
hospitals, university hospitals, private general practice and private pharmacy.  In 2006,  
BBs were the most commonly prescribed antihypertensive medication (25.7DDD/1000 
population/day) followed by the CCBs (19.4), ACEIs ( 15.3), diuretics (8.0) and ARBs 
(4.3) (Rahman and Ming, 2009).  There were 3 drugs whose contribution each made up 
more than 10% of total utilization – metoprolol (12.3DDD/1000 population/day), atenolol 
(12.0) and nifedpine (11.6).  Of these, 2 were BBs and one a CCB.  These 3 drugs were 
used mainly in the public sector (88%).  Overall, 80% of all antihypertensives were 
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utilised in the public sector and 20% in the private sector.  The most popular drugs in the 
private sector were atenolol (3.0DDD/1000 population/day), amlodipine (2.0) and 
enalapril (1.0). 
 
Table 1.4:  Compelling indications for individual drug classes (Chobanian et al., 2003) 
 
Compelling indication* 
Recommended drugs 
Diuretic BB ACEI ARB CCB Aldo-ANT 
Heart failure √ √ √ √  √ 
Postmyocardial infarction  √ √   √ 
High coronary disease risk √ √ √   √ 
Diabetes mellitus √ √ √ √ √  
Chronic kidney disease   √ √ √  
Recurrent stroke √  √    
 
Note: *Compelling indications for antihypertensive drugs are based on benefits  
  from outcome studies or existing clinical guidelines; the compelling indication 
 is managed in parallel with the blood pressure 
 
 
1.3.0   Hypertension around the world   
Hypertension is a massive health problem affecting about 20% of the adult 
population in most countries (Chalmers and Zanchetti, 1996).  Approximately 50 million 
individuals in the United States and 1 billion worldwide are affected by hypertension 
(Chobanian et al., 2003).  The Framingham Heart Study has estimated that individuals 
normotensive at age 55 years have a 90% lifetime risk of developing hypertension (Vasan 
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et al., 2002).  Table 1.5 shows the prevalence of hypertension in 13 countries.  
Worldwide, high blood pressure is estimated to cause 7.1 million deaths, about 13% of 
the global fatality total.  Across WHO regions, research indicates that about 62% of 
strokes and 49% of heart attacks are caused by high blood pressure (World Health 
Organization, 2002) .  
 
 
Table 1.5:  Prevalence of High Blood Pressure (SBP >140 mmHg, DBP >90 mmHg)  
                    by Age Group (World Health Organization, 2008) 
 
Country Age Group Sex Prevalence (%)  
Australia 65 + Both 39.6  
United Kingdom 65+ Both 66.9  
Canada 65+ Both 42.7  
United State of America 18+ Both 21.1  
China 18+ Both 18.8  
India (Jaipur) 20+ Both 51.5  
Russian Federation (Moscow) 25-64 Male Female 
8.2-15 
10.6-14.8 
 
Japan 30+ Male Female 
56.2 
39.7 
 
Saudi Arabia 30+ Both 25.4-26.8  
Malaysia 30+ Both 32.9  
Thailand 35+ Both 22.7  
Indonesia 65+ Male Female 
50.9 
59.6 
 
Singapore 60+ Both 56.1  
 
 
Hypertension is a common problem, with a consistent and continuous risk of 
cardiovascular disease and stroke associated with rising blood pressure levels (Williams 
et al., 2004b).  Furthermore, effective treatment of blood pressures has been shown to 
cause reductions in morbidity and mortality from cardiovascular disease and stroke.  As 
high blood pressure is the most important risk factor for cardiovascular disease, it has 
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been calculated that by achieving the target of 140mmHg, there would be a reduction of 
28-44% in stroke and 20-35% in ischaemic heart disease depending on the age (He and 
Mac Gregor, 2003).  This would prevent approximately 21,400 stroke deaths and 41,400 
ischaemic heart disease deaths each year – and these translate to approximately 42,800 
strokes and 82,800 ischaemic heart diseases saved, making a total of 125,600 events 
saved per year in the United Kingdom alone (He and Mac Gregor, 2003).   
 
1.3.1   Cardiovascular Disease  
Hypertension is one of the major single risk factor contributing to the 
development of cardiovascular morbidity and mortality in the world.  Figure 1.2 shows 
that an estimated 17.5 million people died from cardiovascular disease in 2005, 
representing 30% of all global deaths (World Health Organization, 2008).  Of these 
deaths, 7.6 million were due to heart attacks and 5.7 million were due to stroke.   
Around 80% of these deaths occurred in low and middle income countries.  The 
major causes of cardiovascular disease are tobacco use, physical inactivity and an 
unhealthy diet (World Health Organization, 2008).  If appropriate action is not taken, by 
2015, an estimated 20 million people will die from cardiovascular disease every year, 
mainly form heart attacks and strokes. 
In the United States of America, hypertension affects more than 60 million people 
at a cost exceeding US$ 8 billion (Kjellgren et al., 1995) and cardiovascular disease, 
primarily ischemic heart disease and stroke, are the leading causes of deaths.  It accounts 
for about 40% of all deaths annually and it is estimated that more than 58 million people 
in the United States have some form of cardiovascular disease (Kjellgren et al., 1995).  In 
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1999, the leading causes of death were cardiovascular and neoplasm for both males and 
females.  About 4,700 deaths for 25-34 year olds, 48,600 deaths for 45-54 years olds and 
60% of all deaths in the elderly population (60 years and older) (World Health 
Organization, 2008).   
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Figure 1.2:  Percentage of global deaths by diseases (WHO, 2008) 
 
 
 
In Canada, cardiovascular disease is also the leading cause of morbidity, mortality 
and hospitalization due to illness for men and women.  In 1997, deaths from 
cardiovascular disease were 19,457 (37%). The mortality rate from cardiovascular 
disease was 263 per 100,000; females (258) and males (267) in 1998 (World Health 
Organization, 2008).  . 
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1.3.2   Awareness, Treatment and Control of Hypertension in United States 
 The overall awareness of hypertension has improved from a level of 51% of 
Americans in the period 1979 to 1980 to 70% in 1999 to 2000 (Table 1.6).  The 
percentage of patients with hypertension receiving treatment has increased from 31% to 
59% the percentage of persons with high blood pressure controlled to below 140/90 
mmHg has increased form 10% to 34% in the same period (Chobanian et al., 2003) 
 
1.4.0   Hypertension in Malaysia   
The Third National Health and Morbidity Survey 2006 (NHMS III) reported that 
the prevalence of hypertension in Malaysia was 42.6% (Institute for Public Health, 2008b) 
and the total utilization of antihypertensive was 73.5 DDD/1000 population/day; this 
means about 6-7% of the population were on drug treatment for hypertension (Rahman 
and Sivanandam, 2007).  Among hypertensive patients, 35.8% were aware of their 
hypertension, 31.4% were currently on treatment and only 8.2% had controlled 
hypertension (Institute for Public Health, 2008b).  Concerted public health effort is 
urgently required to improve the detection, treatment and control of hypertension in 
Malaysia.  Malaysia, on the other hand is experiencing a rising incidence of 
cardiovascular disease and it has emerged as the principal cause of mortality and 
hypertension is a prevalent cardiovascular risk factor in our population (Kandiah et al., 
1980, Osman et al., 1984).  Based on Ministry of Health statistics, the leading causes of 
hospitalization in MOH hospitals for the year 2005 includes normal deliveries, followed 
by complications of pregnancy childbirth, accidents and diseases of circulatory system 
(Table 1.7).  However, the major cause of deaths is due to septicaemia followed by heart 
disease (Table 1.8).  
